These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 26148454)
1. Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma. Xie Y; Merkel OM Arch Pharm (Weinheim); 2015 Oct; 348(10):681-8. PubMed ID: 26148454 [TBL] [Abstract][Full Text] [Related]
2. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy. De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301 [TBL] [Abstract][Full Text] [Related]
3. Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. Wu W; Chen H; Li YM; Wang SY; Diao X; Liu KG Int J Clin Exp Pathol; 2014; 7(9):5505-14. PubMed ID: 25337192 [TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma. Asai-Tajiri Y; Matsumoto K; Fukuyama S; Kan-O K; Nakano T; Tonai K; Ohno T; Azuma M; Inoue H; Nakanishi Y Respir Res; 2014 Oct; 15(1):132. PubMed ID: 25344652 [TBL] [Abstract][Full Text] [Related]
5. Before and after endosomal escape: roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency. Kwon YJ Acc Chem Res; 2012 Jul; 45(7):1077-88. PubMed ID: 22103667 [TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. Xie Y; Kim NH; Nadithe V; Schalk D; Thakur A; Kılıç A; Lum LG; Bassett DJP; Merkel OM J Control Release; 2016 May; 229():120-129. PubMed ID: 27001893 [TBL] [Abstract][Full Text] [Related]
8. Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy. Merckx P; Lammens J; Nuytten G; Bogaert B; Guagliardo R; Maes T; Vervaet C; De Beer T; De Smedt SC; Raemdonck K Eur J Pharm Biopharm; 2020 Dec; 157():191-199. PubMed ID: 33022391 [TBL] [Abstract][Full Text] [Related]
9. Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice. Zafra MP; Mazzeo C; Gámez C; Rodriguez Marco A; de Zulueta A; Sanz V; Bilbao I; Ruiz-Cabello J; Zubeldia JM; del Pozo V PLoS One; 2014; 9(3):e91996. PubMed ID: 24637581 [TBL] [Abstract][Full Text] [Related]
10. From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs. Gioia SD; Sardo C; Castellani S; Porsio B; Belgiovine G; Carbone A; Giammona G; Cavallaro G; Conese M Curr Drug Deliv; 2017; 14(2):253-271. PubMed ID: 27557670 [TBL] [Abstract][Full Text] [Related]
11. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Bardoliwala D; Patel V; Javia A; Ghosh S; Patel A; Misra A Ther Deliv; 2019 May; 10(5):311-332. PubMed ID: 31116099 [TBL] [Abstract][Full Text] [Related]
12. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. Zhang M; Jiang H; Wu L; Lu H; Bera H; Zhao X; Guo X; Liu X; Cun D; Yang M J Control Release; 2022 Dec; 352():422-437. PubMed ID: 36265740 [TBL] [Abstract][Full Text] [Related]
13. siRNA delivery to the lung: what's new? Merkel OM; Rubinstein I; Kissel T Adv Drug Deliv Rev; 2014 Aug; 75():112-28. PubMed ID: 24907426 [TBL] [Abstract][Full Text] [Related]
14. Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6. Healey GD; Lockridge JA; Zinnen S; Hopkin JM; Richards I; Walker W PLoS One; 2014; 9(2):e90338. PubMed ID: 24587331 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary gene delivery using polymeric nonviral vectors. Merkel OM; Zheng M; Debus H; Kissel T Bioconjug Chem; 2012 Jan; 23(1):3-20. PubMed ID: 21999216 [TBL] [Abstract][Full Text] [Related]
17. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922 [TBL] [Abstract][Full Text] [Related]
18. pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery. Zhu H; Zhang S; Ling Y; Meng G; Yang Y; Zhang W J Control Release; 2015 Dec; 220(Pt A):529-544. PubMed ID: 26590349 [TBL] [Abstract][Full Text] [Related]
19. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy. Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808 [TBL] [Abstract][Full Text] [Related]
20. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing. Lee SH; Chung BH; Park TG; Nam YS; Mok H Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]